Search

Search Constraints

You searched for: Author/Creator Annunziata, Mario

Search Results

1. 'Secondary chronic myeloid leukemia': comparison between patients previously exposed or not to chemo- and/or radiotherapy. Issue 14 (6th December 2019)

2. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. (17th April 2019)

3. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Issue 10 (October 2015)

4. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Issue 3 (17th April 2019)

5. Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b‐precursor acute lymphoblastic leukaemia: Case reports and literature review. Issue 7 (12th April 2021)

6. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Issue 3 (13th March 2021)

7. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis. Issue 7 (28th April 2018)

8. Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. (7th February 2017)

9. Dasatinib first-line: Multicentric Italian experience outside clinical trials. (January 2016)

10. Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib. Issue 4 (23rd July 2020)